Similar articles

• Antisense therapeutics in oncology: points to consider in their clinical evaluation.

  Mani S, Gu Y, Wadler S, Fingert H. Mani S, et al. Antisense Nucleic Acid Drug Dev. 1999 Dec;9(6):543-7. doi: 10.1089/oli.1.1999.9.543. Antisense Nucleic Acid Drug Dev. 1999. PMID: 10645781
• Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.

  Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM. Hellawell GO, et al. BJU Int. 2003 Feb;91(3):271-7. doi: 10.1046/j.1464-410x.2003.04061.x. BJU Int. 2003. PMID: 12581018
• Chemosensitization by antisense oligonucleotides targeting MDM2.

  Bianco R, Ciardiello F, Tortora G. Bianco R, et al. Curr Cancer Drug Targets. 2005 Feb;5(1):51-6. doi: 10.2174/1568009053332681. Curr Cancer Drug Targets. 2005. PMID: 15720189 Review.
• The role of antisense oligonucleotides in the treatment of bladder cancer.

  Duggan BJ, Gray S, Johnston SR, Williamson K, Miyaki H, Gleave M. Duggan BJ, et al. Urol Res. 2002 Jul;30(3):137-47. doi: 10.1007/s00240-002-0248-3. Epub 2002 May 23. Urol Res. 2002. PMID: 12111175 Review.
• Antisense oligonucleotides and the rational design of new antitumor drugs.

  Prieto J, Hernández-Alcoceba R. Prieto J, et al. Rev Esp Enferm Dig. 2005 Jul;97(7):467-71. doi: 10.4321/s1130-01082005000700001. Rev Esp Enferm Dig. 2005. PMID: 16262525 English, Spanish. No abstract available.